Literature DB >> 21819483

Beneficial effects of Ankaferd Blood Stopper on caustic esophageal injuries: an experimental model.

E Akbal1, S Köklü, G Karaca, H M Astarci, E Koçak, A Taş, Y Beyazit, G Topcu, I C Haznedaroğlu.   

Abstract

Ankaferd Blood Stopper (ABS) is an herbal extract that enhances mucosal healing. The aim of this study was to investigate the efficacy of ABS on the healing of the esophagus and prevention of stricture development after esophageal caustic injuries in rats. The study included 50 rats. Rats were divided into five groups: group 1 (no injury, sham surgery), group 2 (injury + no ABS + study after 2 weeks of injury), group 3 (injury + ABS + study after 2 weeks of injury), group 4 (injury + no ABS + study after 4 weeks of injury), and group 5 (injury + ABS + study after 4 weeks of injury). Standard esophageal burn injury was created by applying 50% NaOH solution to distal esophagus of about 1.5 cm. To rats in the sham group, isotonic solution was given instead of NaOH. ABS (2 mL/day) was given via oral route to group 3 and 5 rats. Fourteen days (group 2 and 3) and 28 days (group 4 and 5) later, all the live rats were killed. The distal esophageal segments of all rats were removed and divided into two equal parts for biochemical and histopathological examination. Mortality rate, weight changes, inflammation, stenosis index (SI), and biochemical measurements were evaluated. The SI was found as 0.31 ± 0.03 in group 1, 0.533 ± 0.240 in group 2, 0.568 ± 0.371 in group 3, 0.523 ± 0.164 in group 4, and 0.28 ± 0.03 in group 5. The SI and inflammation in ABS-treatment group 5 was significantly lower than that in non-treatment group 4 (P= 0.005). There were no significant differences between inflammation and SI among other groups. The mortality rate was 14.2% in group 1, 37.5% in untreated group 2, 14.2% in ABS-treated group 3, 80% in untreated group 4, and 33.3% in ABS-treated group 5. The mortality rate in group 4 was significantly higher than other groups (P= 0.025). Decrease rates in mean body weights of the groups were as follows: group 1, 1%; group 2, 15%; group 3, 14%; group 4, 46%; and group 5, 15%. Biochemical tests other than albumin and creatinine were comparable among the groups. Treatment with ABS prevents inflammation, scar formation, weight loss, and mortality in esophageal caustic injuries. Additional studies to evaluate the clinical benefits of ABS in esophageal caustic injury are recommended.
© 2011 Copyright the Authors. Journal compilation © 2011, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21819483     DOI: 10.1111/j.1442-2050.2011.01231.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  7 in total

1.  The effects of ankaferd blood stopper on the recovery process in an experimental oesophageal perforation model.

Authors:  Necla Gürbüz Sarıkaş; Tanzer Korkmaz; Nurettin Kahramansoy; Ali Kılıçgün; Çetin Boran; Güledal Boztaş
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

2.  Serum M30 and M65 levels and effects of Ankaferd blood stopper in cerulein induced experimental acute pancreatitis model in rats.

Authors:  Bora Aktaş; Omer Başar; Barış Yılmaz; Fuat Ekiz; Akif Altınbaş; Sahin Coban; Fatih Büyükçam; Aynur Albayrak; Zeynep Giniş; Osman Yüksel; Tuncay Delibaşı
Journal:  Int J Clin Exp Med       Date:  2014-07-15

3.  Treatment of hemorrhagic gastritis by Ankaferd blood stopper versus Omeprazole: experimental randomized rat models.

Authors:  Hikmetullah Batgi; Erdem Akbal; Erdem Koçak; Ömer Akyürek; Seyfettin Köklü; Melahat Dönmez; Fahri Güneş
Journal:  Wien Klin Wochenschr       Date:  2015-04-10       Impact factor: 1.704

4.  Beneficial effects of Ankaferd Blood Stopper on dermal wound healing: an experimental study.

Authors:  Cagri Akalin; Serdar Kuru; Aziz Mutlu Barlas; Kemal Kismet; Bugra Kaptanoglu; Aydin Demir; Hesna Muzeyyen Astarci; Huseyin Ustun; Ertugrul Ertas
Journal:  Int Wound J       Date:  2012-09-03       Impact factor: 3.315

5.  Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids.

Authors:  Ahmet Koluman; Nejat Akar; Umit Y Malkan; Ibrahim C Haznedaroglu
Journal:  Biomed Res Int       Date:  2016-01-26       Impact factor: 3.411

6.  The efficacy of Ankaferd Blood Stopper® in an experimental Asherman syndrome model created in rats.

Authors:  Başak Büyük; Fatma Beyazıt
Journal:  Turk J Obstet Gynecol       Date:  2019-03-27

7.  Effects of the Folk Medicinal Plant Extract Ankaferd BloodStopper on the Healing of Colon Anastomosis: An Experimental Study in a Rat Model.

Authors:  Uğur Ekici; Murat Ferhat Ferhatoğlu; Bülent Çitgez; Mehmet Uludağ
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2019-06-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.